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Objective: To assess the incidence of resistance to erythromycin and to the three other macrolide antibiotics most 
extensively used in Italy (azithromycin, clarithromycin and roxithromycin) among clinical strains of Streptococcus 
pyogenes freshly isolated from throat cultures of pediatric patients in an area of Central Italy. 
Methods: Two sets of isolates were examined. The strains of the first set ( n  = 100) were collected according to a protocol 
admitting only throat swabs from untreated patients with symptoms of acute pharyngotonsillitis. The second set ( n  = 
180) consisted of strains isolated from throat cultures during the routine activity of diagnostic laboratories, no particular 
protocol being applied. 
Results: A trimodal distribution of strains was observed in relation to their macrolide susceptibility levels: two clusters 
were constituted by highly susceptible and highly resistant strains, respectively; a third, middle cluster consisted of 
strains displaying low-level resistance (or even intermediate susceptibility, in a minority of isolates, to clarithromycin). 
The distribution of individual isolates in the three modal clusters was the same with all four drugs. Both MIC ranges and 
MlC50s almost overlapped in the isolates of the two sets, whereas MlCsos were far higher in the strains of the second 
set (4 pg/mL for clarithromycin, 8 pg/mL for erythromycin and azythromycin, and 16 p g h L  for roxithromycin) than in  
those of the first (0.125 pg/mL for all four drugs). Resistant strains were 5% among the isolates of the first set and three 
times as many among those of the second. 
Conclusions: The lower incidence of macrolide resistance recorded in the first set is probably more reliable: the 
threefold incidence observed in the second set may be overestimated due to the lower frequency of strains involved in 
drug-responsive infections and to the increased occurrence of strains from unsuccessfully treated patients. 
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INTRODUCTION 
A re-emergence of severe Streptococcus pyogenes infec- 
tions and of their suppurative and non-suppurative 
sequelae has been reported over the last decade in 
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Europe and North America [1,2]. AU S. pyogenes 
isolates are susceptible to penicillin, the drug of choice 
for the treatment of group A streptococcal infections. 
Penicillin failures may, however, occur due to  causes 
which include inadequate dosage, poor patient com- 
pliance or tolerance phenomena [3]; a possible role €or 
P-lactamase production by the surrounding oropharyn- 
geal flora [4] is more controversial. 
Erythromycin is usually recommended as the alter- 
native treatment for group A streptococcal pharyngo- 
tonsillitis only in patients allergic to penicilhns or 
in cases of penicilhn failure [ 5 ] .  In fact, however, 
macrolide antibiotics are extensively used in these 
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infections, and generally in infections of the upper 
respiratory tract, indeed even more so since the intro- 
duction of new molecules with an expanded spectrum 
(including in particular Haemophilus injuenzae), better 
pharmacologic properties and fewer gastrointestinal 
side effects as compared with erythromycin [6]. The 
resistance of S. pyogenes to erythromycin was first 
reported in the late 1950s [7]. Since then, this resistance 
trait has been found, with variable but generally low 
incidence, in several countries [8,9]. Increasing rates, 
with peaks exceelng 80%, associated with the 
d a s i o n  of new types, were reported in Japan in the 
1970s [lo-131. In more recent years, while resistance 
rates are still quite low according to some studies 
[ 14-1 71, an increased incidence of erythromycin 
resistance has been reported in other surveys from 
different parts of the world [18-221. For Italy, only 
preliminary and rather heterogeneous data are so far 
available [23-251. 
In this study, two different sets of S.  pyogenes isolates 
obtained from throat cultures of patients living in the 
same area of Centrd Italy were examined. One set of 
strains came &om untreated patients with symptoms 
of acute pharingotonsillitis. The second set of strains 
was isolated during the routine activity of diagnostic 
laboratories of the same area, no particular protocol 
being applied. All strains were tested for their sus- 
ceptibility to erythromycin and to the three other 
macrolide antibiotics most extensively used in Italy 
(azithromycin, clarithromycin and roxithromycin). The 
difFerent resistance rates recorded in the isolates of the 
two sets, in spite of substantial cross-response to the 
four macrolide antibiotics, suggest that the criteria for 
specimen collection are likely to influence the reported 
incidence of macrolide resistance. 
MATERIALS AND METHODS 
Bacterial strains 
Two separate sets of S. pyogenes strains were examined. 
All strains were isolated over a 6-month period 
(October 1995 to March 1996) &om throat cultures 
of pediatric patients living in an area of Central Italy 
(part of Marche and Umbria, with a population of 
approximately one million). Multiple isolates from the 
same patient were avoided. The first set, designed to be 
representative of the variety of S. pyogenes strains 
causing acute pharingotonsillitis in the community, 
included 100 isolates collected according to a protocol 
requiring throat cultures to be obtained from untreated 
patients (who had not received antibiotics for at least 1 
month prior to throat sampling) diagnosed with this 
infection. The second set included 180 throat strains 
isolated in different diagnostic laboratories in the area 
in the course of their routine activity, without the 
application of any protocol. 
P-Hemolync colonies were identified as S. pyogenes 
using bacitracin disks (Difco Laboratories, Detroit, 
MI, USA) and a latex agglutination assay (Streptex; 
Wellcome, Dartford, UK). The strains were maintained 
in glycerol at -70°C until all isolates were collected, 
and subcultured twice on blood agar before suscept- 
ibility testing. 
Antibiotics 
Erythromycin and roxithromycin were purchased 
from Sigma Chemical Co., St Louis, MO, USA. 
Azithromycin and clarithromycin were obtained from 
Pfizer Inc., New York, Ny, USA, and Abbott 
Laboratories, Abbott Park, IL, USA, respectively. 
Susceptibility testing 
Minimum inhibitory concentrations (MICs) were 
determined by a standard microdilution procedure [26] 
using Mueller-Hinton I1 broth (Becton Dickinson 
Microbiology Systems, Cockeysville, MD, USA) 
supplemented with 3% lysed horse blood as the test 
medium. The inoculum was 5 x lo5 CFU/mL. The 
antibiotics were tested at final concentrations (prepared 
&om twofold dilutions) ranging fkom 0.03 to 128 
pg/mL. The MIC was defined as the lowest concen- 
tration which yielded no visible growth. The following 
MIC breakpoints suggested by the National Com- 
mittee for Clinical Laboratory Standards [27] were 
considered for erythromycin, clarithromycin, and roxi- 
thromycin (susceptible, 10.25 p g / d ;  intermediate, 
0.5 pg/mL; resistant, 21 pg/mL) and for azythromycin 
(susceptible, 10.5 pg/mL; intermediate, 1 p g / d ;  
resistant, 22 pg/mL). Enterococnrsfaecalis ATCC 29212 
and Staphylococcus aureus ATCC 29213 were used as 
controls. 
RESULTS 
The activities of the four macrolide antibiotics against 
the S. pyogenes isolates of the two sets are summarized 
in Tables 1 and 2. 
A comparison of these results shows that both MIC 
ranges and MICm almost overlapped in the two sets, 
whereas MIC90s were far higher in the strains of the 
second set (4 pg/mL for clarithromycin, 8 pg/mL for 
erythromycin and azithromycin, and 16 pg/mL for 
roxithromycin) than in those of the first (0.12 p g / d  
for all four drugs). Among the 100 isolates of the first 
set, the same five strains were cross-resistant to all four 
macrolide antibiotics, and no intermediate value was 
observed. Among the 180 isolates of the second set, 
the same 27 strains were resistant to erythromycin, 
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Table 1 Activities of erythromycin, azithromycin, clarithromycin and roxithromycin against 100 S. pyogenes isolates of the 
first set (i.e. collected according to a protocol requiring throat swabs to be obtained &om untreated patients with symptoms 
of acute &arynpotonsillitis) 
No. (cumdative no.) and cumulative % of strains inhibited at MIC (w/mL) 
Antibiotic 50.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 
~ _ _ _ _ _  ~ 
Erythromycin 39 (39) 
39% 
Azithromycin 35 (35) 
35% 
Clarithromycin 45 (45) 
45% 


































Table 2 Activities of erythromycin, azithromycin, clarithromycin and roxithromycin against 180 S. ppgenes strains of the 
second set (i.e. isolated in the routine activity of diagnostic laboratories, no particular protocol being applied) 
~~~ 
No. (cumulative no.) and cumulative % of st ra ins  inhibited at MIC (pg/mL) 
Antibiotic 20.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >I28 
~~ 
Erythromycin 80 (80) 
44 4% 
Avthromycin 72 (72) 
40% 
Clarithromycln 94 (94) 
52.2% 
Romthromyan 70 (70) 
38.9% 
~ ~~ 
69 (149) 4 (153) 
82.8% 85% 




73 (143) 10 (153) 
79.4% 85% 
















6 (163) 10 (173) 
90.6% 96.1% 




3 (161) 6 (167) 6 (173) 









azithromycin and roxithromycin, and resistant (25 
strains) or intermediate (two strains) to clarithromycin. 
The difference in the resistance rate between the 
first set isolates (five of 100, 5%) and the second set 
isolates (27 of 180, 15%) was statistically significant 
(p = 0.01 09). 
A trimodal distribution in relation to macrolide 
susceptibihty was evident in the isolates of both sets. 
Two clusters consisted of highly susceptible and highly 
resistant strains, respectively. The modal MIC was 
SO.12 pg/mL for azithromycin and clarithromycin and 
10.25 p g / d  for erythromycin and roxithromycin 
within the highly susceptible cluster, and >128 pg/mL 
for all drugs withm the highly resistant cluster. A 
thrd, middle cluster was separated fiom both highly 
susceptible and highly resistant strains by a variable 
number of MIC values not recorded for any test strain. 
Among the first set strains, this middle cluster was 
represented by two isolates (2%) displaying low-level 
resistance (8 to 16 p g / d )  to all four macrolides. 
Among the second set strains, it was represented by 20 
isolates (1 1.1%) displaying low-level resistance (1 to 32 
pg/mL) to erythromycin, azithromycin and roxithro- 
mycin, and low-level resistance (2 to 8 pg/mL) or, less 
ofien, intermediate susceptibility (0.5 pg/mL) to clari- 
thromycin. The three modal clusters were distributed 
rather homogeneously within the geographic area 
considered. 
DISCUSSION 
There was substantial cross-response of the S. pyogenes 
test strains to the four macrolide antibiotics, in the sense 
that the distribution of individual isolates over the three 
distinct modal clusters (lughly susceptible, middle and 
highly resistant) was the same with all four macrolide 
antibiotics. It is worth stressing that the occurrence, 
among resistant strains, of two distinct degrees of 
resistance @ugh or low) separated by a clear solution of 
continuity had already been noted in early studies 
of erythromycin resistance in S. pyogenes [8,9]. 
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Interestingly, resistant strains were three times more 
frequent within the second than the first set, this 
difference being essentially accounted for by low-level 
resistant strains. By virtue of the criterion applied for 
collection, the isolates of the first set - i.e. those 
obtained fiom untreated patients with symptoms of 
acute pharyngotonsdhtis - are lrkely to be repre- 
sentative of the actual variety of S. pyogenes strains 
currently involved in acute pharyngotonsillitis in the 
community living in the area covered by our survey. 
This is less true of the second set st ra ins ,  isolated fiom 
throat swabs routinely processed in diagnostic labora- 
tories of the same area, with no particular protocol 
applied. In fact, in patients receiving macrolide anti- 
biotics for acute pharyngotonsillitis or other acute 
infections of the higher respiratory tract, therapy is 
given in most instances without prior microbiological 
investigation. Ths empirical therapy is successful in the 
majority of patients, and ofien only in case of failure is 
the diagnostic laboratory applied to for help. This is 
why the isolates of the first set probably reflect more 
closely the incidence of macrolide resistance occurring 
in the community. The threefold incidence observed in 
the second set may be overestimated due to the lower 
frequency of strains involved in drug-responsive 
infections and to the increased occurrence of strains 
from unsuccessfidly treated patients in the throat swabs 
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